Tiziana Life Sciences PLC (TLSA) announces new biomarker data

Data show that its nasal candidate drug Foralumab can downregulate inflammatory responses in the cerebrospinal fluid of patients with non-active secondary progressive multiple sclerosis with underlying disability progression, while upregulating neuroprotective pathways. In addition, the effect of this drug is correlated with a reduction in microglial activation as observed by positron emission tomography. These findings provide new insights into the therapeutic mechanism of Foralumab. The study suggests that this therapy may bring new hope to patients with this difficult-to-treat form of multiple sclerosis by modulating the immune environment of the central nervous system.